RFK Jr. Launches His Latest MAHA Initiative

RFK Jr. just launched a crusade to yank millions of Medicare patients off antidepressants, promising therapy instead—but will it save lives or spark a mental health crisis?

Story Snapshot

Health Secretary Robert F. Kennedy Jr. announced the campaign at the MAHA Institute’s Mental Health and Overmedicalization Summit in early May 2026.
Initiative pushes de-prescribing antidepressants for Medicare enrollees, favoring non-drug options like therapy and clinician training on risks and tapering.
Kennedy insists no mandates, just “information and support” for informed choices, amid his past claims linking SSRIs to violence and addiction.
Critics warn of therapy shortages and echoes of 2004 FDA warnings that slashed prescriptions but spiked youth suicides.
MAHA Commission, established February 2025, drives the effort targeting overprescription in a $20 billion SSRI market.

Announcement Details at MAHA Summit

Robert F. Kennedy Jr. spoke at the Make America Healthy Again Institute’s summit on Monday. He unveiled the HHS campaign to cut antidepressant reliance among Medicare’s 65 million enrollees. Clinicians receive encouragement to de-prescribe, replacing drugs with therapy. Training covers psychiatric medication risks and slow tapering to dodge withdrawal. Kennedy clarified: “We’re not telling you to stop any medications.” The focus stays on patient-led decisions with evidence-based paths.

Kennedy’s History of SSRI Skepticism

Kennedy linked SSRIs to a Minnesota school shooting in August 2025 on Fox News. In November 2025, he directed the CDC via X post to probe SSRIs’ role in mass violence. January 2026 saw his claim that antidepressants prove harder to quit than heroin, later fact-checked. The MAHA Commission, via Executive Order 14212 in February 2025, assessed threats from SSRIs and similar drugs at its March meeting. Seven HHS officials joined summit panels like “Psychiatric Drugs: Informed Choice.”

Opposition from Medical Groups and Democrats

The California State Association of Psychiatrists rebutted Kennedy’s violence claims in September 2025, calling them untrue and harmful for deterring care. APA’s Gregory Scott Brown affirmed SSRIs as safe, effective, with no evidence they cause violence alone. A March 20, 2025, congressional letter from Rep. Balint urged Kennedy against undermining necessary treatments. Protect Our Care criticized the plan May 5, 2026, citing Trump budget limits and therapy access woes—82.7% of psychotherapists shun Medicare.

Potential Impacts on Patients and Policy

Medicare patients, where 15-20% use antidepressants, face de-prescribing pushes amid high depression rates. Short-term, clinician training may spark hesitancy. Long-term, reduced SSRI use mirrors 2004 FDA black-box warnings: prescriptions dropped 20%, youth suicides rose 14%. Therapy demand surges, but shortages loom—one-third of therapists reject private insurance. Economic upsides include $10 billion annual drug savings; risks involve untreated depression and stigma revival. Kennedy’s approach aligns with conservative values of personal choice over pharma dependence, though facts on violence links remain thin—common sense demands rigorous studies before broad shifts.

RFK Jr. Launches His Latest MAHA Project — Getting Americans Off Antidepressants https://t.co/pxMO3Qi9yd #gatewaypundit via @gatewaypundit To think this was all possible following the Obama Biden era… What a world we may have!

— markgoethel (@markgoethel) May 6, 2026

Broader MAHA Context and Uncertainties

This fits Kennedy’s MAHA agenda against chronic disease epidemics, less divisive than vaccines. HHS overhaul under Trump empowers the push, with CDC and NIH studying SSRI effects. Withdrawal symptom rates stay unclear. No 2026 outcomes exist yet. Supporters hail empowerment; critics fear politicized science scaring patients, as post-2004 data showed thousands of lost lives from avoided care. Balanced scrutiny serves American priorities: real science, patient autonomy, and avoiding overreach.